Bio-Gene Technology Dirección

Dirección controles de criterios 0/4

Bio-Gene Technology's El consejero delegado es Tim Grogan , nombrado en Aug 2023, tiene un mandato de menos de un año. posee directamente 0.03% de las acciones de la empresa, con un valor de A$3.21K . La antigüedad media del equipo directivo y del consejo de administración es de 0.3 años y 0.7 años, respectivamente.

Información clave

Tim Grogan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.03%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

CEO

Tim Grogan

less than a year

Permanencia

Mr. Timothy Owen Grogan, LLB, B.Sc., also known as Tim, serves as Managing Director, Chief Executive Officer & Director of Bio-Gene Technology Limited since August 28, 2023. He serves as a Director of Cons...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger McPherson	Interim CFO & Company Secretary	less than a year	AU$146.51k	0.61% A$ 91.8k
Peter May	Executive Director of Research & Development and Executive Director	6.3yrs	AU$246.25k	0.91% A$ 138.2k
Timothy Grogan	MD, CEO & Director	less than a year	sin datos	0.030% A$ 4.5k

0.7yrs

Permanencia media

Equipo directivo experimentado: BGTEl equipo directivo de la empresa no se considera experimentado ( 0.3 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter May	Executive Director of Research & Development and Executive Director	8.9yrs	AU$246.25k	0.91% A$ 138.2k
Timothy Grogan	MD, CEO & Director	less than a year	sin datos	0.030% A$ 4.5k
Douglas Rathbone	Adviser to the Board	6.3yrs	sin datos	sin datos
Peter Beetham	Member of Scientific Advisory Board	less than a year	AU$45.50k	0.030% A$ 4.5k
Andrew Guthrie	Non-Executive Director	3yrs	AU$57.62k	0.13% A$ 20.0k
Catherine Hill	Member of the Scientific Advisory Board	6.2yrs	sin datos	sin datos
Neil Anderson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Andrew Bartholomaeus	Member of Scientific Advisory Board	no data	sin datos	sin datos
Huong Soo Ding	Non-Executive Chairman	less than a year	AU$6.97k	0.060% A$ 9.1k
Christopher Ramsay	Non-Executive Director	less than a year	AU$6.97k	sin datos
Chris Ramsey	Non Executive Director	less than a year	sin datos	0.059% A$ 8.9k

1.0yrs

Permanencia media

Junta con experiencia: BGTno se consideran experimentados ( 0.7 años de permanencia media), lo que sugiere un nuevo consejo.

Bio-Gene Technology Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

No independent directors

Bio-Gene Technology Limited Approves the Election of Alex Ding as Director

Bio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFO

Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary

No independent directors

Recent updates

New minor risk - Financial data availability

No independent directors

No independent directors

Bio-Gene Technology Limited Approves the Election of Alex Ding as Director

Bio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFO

Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary

No independent directors

Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023

New minor risk - Shareholder dilution

No independent directors

New major risk - Financial position

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)

Bio-Gene Technology Limited Announces Managing Director Changes

No independent directors

New major risk - Market cap size

No independent directors

Bio-Gene Technology Limited Announces Changes to the Board

No independent directors

No independent directors

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)

No independent directors

No independent directors

Bio-Gene Technology Limited Submits Application to Secure Additional IP for Qcidetm

No independent directors

Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022

Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)

No independent directors

Bio-Gene Technology Limited Announces Positive Stored Grain Pest Results

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory Affairs

Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in funding

Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in funding

Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021

Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of Activity

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)

Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity Studies

Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020

Bio-Gene Technology Limited Announces Changes of Directors

Full year earnings released - AU$0.016 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media